Published in Scand J Infect Dis on May 12, 2011
Resolving pertussis immunity and vaccine effectiveness using incidence time series. Expert Rev Vaccines (2012) 0.86
Development of improved pertussis vaccine. Hum Vaccin Immunother (2014) 0.83
Pertussis. A reemerging and an underreported infectious disease. Saudi Med J (2014) 0.80
Bordetella parapertussis survives inside human macrophages in lipid raft-enriched phagosomes. Infect Immun (2014) 0.77
Bordetella Adenylate Cyclase-Hemolysin Toxins. Toxins (Basel) (2017) 0.75
Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog (2005) 2.71
Multiple-locus variable-number tandem repeat analysis of Dutch Bordetella pertussis strains reveals rapid genetic changes with clonal expansion during the late 1990s. J Bacteriol (2004) 2.58
Multilocus sequence typing of Bordetella pertussis based on surface protein genes. J Clin Microbiol (2002) 2.02
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
Crucial role of antibodies to pertactin in Bordetella pertussis immunity. J Infect Dis (2003) 1.73
Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands. Pediatr Infect Dis J (2008) 1.69
Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis. PLoS One (2010) 1.61
Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines. Microbiology (2002) 1.46
Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect (2005) 1.36
Small mutations in Bordetella pertussis are associated with selective sweeps. PLoS One (2012) 1.35
Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33
Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants? J Infect Dis (2003) 1.29
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics (2008) 1.26
Comparative genomics of Bordetella pertussis reveals progressive gene loss in Finnish strains. PLoS One (2007) 1.26
Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants? Vaccine (2013) 1.24
Pathogen adaptation under imperfect vaccination: implications for pertussis. Proc Biol Sci (2005) 1.24
Improving pertussis vaccination. Hum Vaccin (2009) 1.12
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun (2008) 1.09
Antigenic divergence between Bordetella pertussis clinical isolates from Moscow, Russia, and vaccine strains. Clin Vaccine Immunol (2007) 1.05
Bordetella pertussis strains circulating in Europe in 1999 to 2004 as determined by pulsed-field gel electrophoresis. J Clin Microbiol (2007) 1.04
Preclinical and clinical safety studies on DNA vaccines. Hum Vaccin (2006) 1.03
Bordetella pertussis clones identified by multilocus variable-number tandem-repeat analysis. Emerg Infect Dis (2010) 1.03
Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs. Vaccine (2011) 1.03
Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine (2004) 1.02
The role of Toll-like receptor-4 in pertussis vaccine-induced immunity. BMC Immunol (2008) 0.99
Characterization of Bordetella holmesii isolates from patients with pertussis-like illness in The Netherlands. FEMS Immunol Med Microbiol (2011) 0.99
Pertussis: a matter of immune modulation. FEMS Microbiol Rev (2011) 0.99
An investigation into the cause of the 1983 whooping cough epidemic in the Netherlands. Vaccine (2009) 0.96
SNP-based typing: a useful tool to study Bordetella pertussis populations. PLoS One (2011) 0.93
Two-component cluster analysis of a large serodiagnostic database for specificity of increases of IgG antibodies against pertussis toxin in paired serum samples and of absolute values in single serum samples. Clin Vaccine Immunol (2012) 0.92
Studies on Prn variation in the mouse model and comparison with epidemiological data. PLoS One (2011) 0.91
The Bordetella pertussis virulence factor P.69 pertactin retains its immunological properties after overproduction in Escherichia coli. Protein Expr Purif (2005) 0.91
Epitope structure of the Bordetella pertussis protein P.69 pertactin, a major vaccine component and protective antigen. Infect Immun (2004) 0.90
Estimation of household transmission rates of pertussis and the effect of cocooning vaccination strategies on infant pertussis. Epidemiology (2012) 0.90
Immunodominance in mouse and human CD4+ T-cell responses specific for the Bordetella pertussis virulence factor P.69 pertactin. Infect Immun (2008) 0.89
Association of Bordetella pertussis with host immune cells in the mouse lung. Microb Pathog (2003) 0.88
Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies. Vaccine (2009) 0.88
Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis. Vaccine (2006) 0.86
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009. J Clin Microbiol (2012) 0.86
Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin. Scand J Infect Dis (2008) 0.85
Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice. Clin Vaccine Immunol (2007) 0.83
Bordetella pertussis isolates, Finland. Emerg Infect Dis (2005) 0.81
Comparative gene expression profiling in two congenic mouse strains following Bordetella pertussis infection. BMC Microbiol (2007) 0.81
Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies. Vaccine (2013) 0.80
Complement evasion by Bordetella pertussis: implications for improving current vaccines. J Mol Med (Berl) (2015) 0.80
The role of peptide loops of the Bordetella pertussis protein P.69 pertactin in antibody recognition. Vaccine (2007) 0.80
Molecular typing of Bordetella parapertussis isolates circulating in Pakistan. FEMS Immunol Med Microbiol (2011) 0.78
Characterization of Bordetella pertussis clinical isolates that do not express the tracheal colonization factor. FEMS Immunol Med Microbiol (2007) 0.77
A novel strategy to mimic discontinuous protective epitopes using a synthetic scaffold. Vaccine (2007) 0.76
Seroepidemiology of Bordetella pertussis infections in the twin cities of Pakistan. N Am J Med Sci (2009) 0.76
Effects of a diphtheria-tetanus-acellular pertussis vaccine on immune responses in murine local lymph node and lung allergy models. Clin Vaccine Immunol (2007) 0.75
[Pertussis in the Netherlands]. Ned Tijdschr Geneeskd (2010) 0.75
Pertussis in infancy and the association with respiratory and cognitive disorders at toddler age. Vaccine (2011) 0.75